Evidence map›Paper›PMID 33208745›Full record

ArticleNature communications2020

Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease.

Kate L Bowerman, Saima Firdous Rehman, Annalicia Vaughan, Nancy Lachner, Kurtis F Budden, Richard Y Kim, David L A Wood, Shaan L Gellatly, Shakti D Shukla, Lisa G Wood and 4 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04876833 (Characteristics of Intestinal Microbiome in the Progression of Early Chronic Obstructive Pulmonary Disease), which is not on this map. Cited by 281 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
281citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04876833 unknown statusnot on this mapstarted 2021, after this paper: background citation

Characteristics of Intestinal Microbiome in the Progression of Early Chronic Obstructive Pulmonary Disease

Typeobservational_patient_registrySponsorSecond Affiliated Hospital of Xi'an Jiaotong UniversityRan2021 to 2022Enrolled120ConditionsChronic Obstructive Pulmonary Disease
3 · Its place in the literature

Who cites it

281 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Association of gut microbiome dysbiosis with the progression of atrial fibrillation: A systematic review.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2023
    Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Gut microbiota associate with disease severity and survival in idiopathic pulmonary fibrosis.American journal of respiratory and critical care medicine · 2026
    Article
  18. Review
  19. Gut Microbiota-Derived Short-Chain Fatty Acids Driven by N-Carbamylglutamate Alleviates Premature Ovarian Failure Through Suppressing Ferroptosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  20. Review

221 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kate L BowermanAustralian Centre for Ecogenomics, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.ORCID 0000-0003-2339-114X
Saima Firdous RehmanPriority Research Centre for Healthy Lungs, Hunter Medical Research Institute, and The University of Newcastle, Newcastle, NSW, Australia.ORCID 0000-0001-6269-355X
Annalicia VaughanThoracic Research Centre, Faculty of Medicine, The University of Queensland, and Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, QLD, Australia.
Nancy LachnerAustralian Centre for Ecogenomics, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.
Kurtis F BuddenPriority Research Centre for Healthy Lungs, Hunter Medical Research Institute, and The University of Newcastle, Newcastle, NSW, Australia.
Richard Y KimCentre for Inflammation, Centenary Institute & University of Technology Sydney, School of Life Sciences, Faculty of Science, Sydney, NSW, Australia.
David L A WoodAustralian Centre for Ecogenomics, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.
Shaan L GellatlyPriority Research Centre for Healthy Lungs, Hunter Medical Research Institute, and The University of Newcastle, Newcastle, NSW, Australia.
Shakti D ShuklaPriority Research Centre for Healthy Lungs, Hunter Medical Research Institute, and The University of Newcastle, Newcastle, NSW, Australia.ORCID 0000-0002-5796-0171
Lisa G WoodPriority Research Centre for Healthy Lungs, Hunter Medical Research Institute, and The University of Newcastle, Newcastle, NSW, Australia.
Ian A YangThoracic Research Centre, Faculty of Medicine, The University of Queensland, and Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, QLD, Australia.
Peter A WarkPriority Research Centre for Healthy Lungs, Hunter Medical Research Institute, and The University of Newcastle, Newcastle, NSW, Australia.
Philip HugenholtzAustralian Centre for Ecogenomics, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.ORCID 0000-0001-5386-7925
Philip M HansbroPriority Research Centre for Healthy Lungs, Hunter Medical Research Institute, and The University of Newcastle, Newcastle, NSW, Australia. philip.hansbro@uts.edu.au.ORCID 0000-0002-4741-3035

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is the third commonest cause of death globally, and manifests as a progressive inflammatory lung disease with no curative treatment. The lung microbiome contributes to COPD progression, but the function of the gut microbiome remains unclear. Here we examine the faecal microbiome and metabolome of COPD patients and healthy controls, finding 146 bacterial species differing between the two groups. Several species, including Streptococcus sp000187445, Streptococcus vestibularis and multiple members of the family Lachnospiraceae, also correlate with reduced lung function. Untargeted metabolomics identifies a COPD signature comprising 46% lipid, 20% xenobiotic and 20% amino acid related metabolites. Furthermore, we describe a disease-associated network connecting Streptococcus parasanguinis_B with COPD-associated metabolites, including N-acetylglutamate and its analogue N-carbamoylglutamate. While correlative, our results suggest that the faecal microbiome and metabolome of COPD patients are distinct from those of healthy individuals, and may thus aid in the search for biomarkers for COPD.

Indexed as

Gastrointestinal MicrobiomeAdultAmino AcidsBacteriaCase-Control StudiesFecesFemaleHumansLipid MetabolismLipidsLungMaleMetabolomicsMicrobiotaMiddle AgedPulmonary Disease, Chronic ObstructiveAmino AcidsLipids

Identifiers

PMID33208745
PMCPMC7676259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.